CF PharmTech Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Public

  • Employees
  • 625

Employees

  • Stock Symbol
  • 02652

Stock Symbol

  • Share Price
  • $0.62
  • (As of Friday Closing)

CF PharmTech General Information

Description

CF PharmTech Inc is engaged in inhalation drug delivery technology. It is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs. The Company is a specialist in the development of complex inhalation formulations with high barriers to entry, and a platform-based pharmaceutical company with integrated capabilities spanning device engineering, precision drug delivery, international regulatory filing, and commercialization. Leveraging its self-developed, globally integrated end-to-end capabilities, from exhalation-powered nasal spray delivery systems and liposomal inhalation technology to small interfering RNA (siRNA) nucleic acid delivery platforms. Its therapeutic areas encompass respiratory diseases and nasal diseases.

Contact Information

Formerly Known As
Suzhou Changfeng Pharmaceutical
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • Number16, Hucundang Road
  • Xiangcheng Economic Development Zone
  • Suzhou, Jiangsu 215000
  • China
+86 0512
Primary Industry
Drug Delivery
Other Industries
Pharmaceuticals
Stock Exchange
HKG
Corporate Office
  • Number16, Hucundang Road
  • Xiangcheng Economic Development Zone
  • Suzhou, Jiangsu 215000
  • China
+86 0512

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CF PharmTech Stock Performance

As of 13-Nov-2026, CF PharmTech’s stock price is $0.62. Its current market cap is $267M with 432M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.62 $0.65 $0.62 - $5.05 $267M 432M 2.97M

CF PharmTech Financials Summary

As of 30-Jun-2026, CF PharmTech has a trailing 12-month revenue of $62.4M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 911,433 1,874,614
Revenue 62,423 60,145 84,699 78,647
EBITDA 6,970 7,717 11,226 10,296
Net Income (971) 346 2,939 4,484
Total Assets 255,731 253,872 172,467 160,137
Total Debt 31,251 20,804 10,835 3,091
Public Fundamental Data provided by Morningstar, Inc. disclaimer

CF PharmTech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CF PharmTech‘s full profile, request access.

Request a free trial

CF PharmTech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
CF PharmTech Inc is engaged in inhalation drug delivery technology. It is dedicated to building multidisciplinary bridge
Drug Delivery
Suzhou, China
625 As of 2026

Framingham, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CF PharmTech Competitors (1)

One of CF PharmTech’s competitors is Pulmatrix, a Formerly VC-backed company based in Framingham, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pulmatrix Formerly VC-backed Framingham, MA
You’re viewing 1 of 1 competitors. Get the full list »

CF PharmTech Patents

CF PharmTech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026214612-A1 Sirna for inhibiting mmp7, modified form thereof, and use thereof Pending 10-Apr-2025
WO-2026179900-A1 Sirna for inhibiting tslp, and modified form and use thereof Pending 28-Feb-2025
WO-2026144627-A1 Dry powder composition of treprostinil derivative, and use thereof Pending 31-Dec-2024
WO-2026050883-A1 Atomization drug delivery device Pending 03-Sep-2024
FR-3165784-A3 Atomizing drug delivery device Pending 03-Sep-2024 A61M15/0021
To view CF PharmTech’s complete patent history, request access »

CF PharmTech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CF PharmTech ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view CF PharmTech’s complete esg history, request access »

CF PharmTech FAQs

  • When was CF PharmTech founded?

    CF PharmTech was founded in 2007.

  • Where is CF PharmTech headquartered?

    CF PharmTech is headquartered in Suzhou, China.

  • What is the size of CF PharmTech?

    CF PharmTech has 625 total employees.

  • What industry is CF PharmTech in?

    CF PharmTech’s primary industry is Drug Delivery.

  • Is CF PharmTech a private or public company?

    CF PharmTech is a Public company.

  • What is CF PharmTech’s stock symbol?

    The ticker symbol for CF PharmTech is 02652.

  • What is the current stock price of CF PharmTech?

    As of 13-Nov-2026 the stock price of CF PharmTech is $0.62.

  • What is the current market cap of CF PharmTech?

    The current market capitalization of CF PharmTech is $267M.

  • What is CF PharmTech’s current revenue?

    The trailing twelve month revenue for CF PharmTech is $62.4M.

  • Who are CF PharmTech’s competitors?

    Pulmatrix is a competitor of CF PharmTech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process